JP2011505120A5

JP2011505120A5 -

Download PDF

Info

Publication number: JP2011505120A5
Authority: JP; Japan
Prior art keywords: axl; antibody; cells; antibodies; seq
Prior art date: 2008-11-12
Legal status : Granted

Application number

JP2010532510A

Other languages

English (en)

Japanese (ja)

Other versions

JP5769969B2 (ja

JP2011505120A (ja

Filing date

2008-11-12

Publication date

2012-01-05

2008-11-12 Application filed filed Critical

2008-11-12 Priority claimed from PCT/EP2008/009548 external-priority patent/WO2009062690A1/en

2011-02-24 Publication of JP2011505120A publication Critical patent/JP2011505120A/ja

2012-01-05 Publication of JP2011505120A5 publication Critical patent/JP2011505120A5/ja

2015-08-26 Application granted granted Critical

2015-08-26 Publication of JP5769969B2 publication Critical patent/JP5769969B2/ja

Status Expired - Fee Related legal-status Critical Current

2028-11-12 Anticipated expiration legal-status Critical

Links

102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 175
101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 174
206010028980 Neoplasm Diseases 0.000 claims description 79
241000282414 Homo sapiens Species 0.000 claims description 73
238000000034 method Methods 0.000 claims description 59
230000001404 mediated effect Effects 0.000 claims description 56
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 51
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
239000002246 antineoplastic agent Substances 0.000 claims description 49
230000026731 phosphorylation Effects 0.000 claims description 48
238000006366 phosphorylation reaction Methods 0.000 claims description 48
230000014509 gene expression Effects 0.000 claims description 47
150000001413 amino acids Chemical class 0.000 claims description 46
239000013598 vector Substances 0.000 claims description 44
150000007523 nucleic acids Chemical group 0.000 claims description 42
201000010099 disease Diseases 0.000 claims description 41
230000000694 effects Effects 0.000 claims description 33
230000003463 hyperproliferative effect Effects 0.000 claims description 29
108020004707 nucleic acids Proteins 0.000 claims description 29
102000039446 nucleic acids Human genes 0.000 claims description 29
206010027476 Metastases Diseases 0.000 claims description 26
238000011282 treatment Methods 0.000 claims description 26
230000004663 cell proliferation Effects 0.000 claims description 22
230000009401 metastasis Effects 0.000 claims description 22
239000008194 pharmaceutical composition Substances 0.000 claims description 22
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 19
201000005202 lung cancer Diseases 0.000 claims description 19
208000020816 lung neoplasm Diseases 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 18
230000002018 overexpression Effects 0.000 claims description 17
229920001184 polypeptide Polymers 0.000 claims description 17
102000004196 processed proteins & peptides Human genes 0.000 claims description 17
108090000765 processed proteins & peptides Proteins 0.000 claims description 17
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
208000026310 Breast neoplasm Diseases 0.000 claims description 15
241001465754 Metazoa Species 0.000 claims description 15
206010006187 Breast cancer Diseases 0.000 claims description 14
108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
230000012292 cell migration Effects 0.000 claims description 14
230000011664 signaling Effects 0.000 claims description 14
230000006909 anti-apoptosis Effects 0.000 claims description 13
230000015572 biosynthetic process Effects 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
229940079593 drug Drugs 0.000 claims description 11
230000033115 angiogenesis Effects 0.000 claims description 10
208000013403 hyperactivity Diseases 0.000 claims description 9
230000001580 bacterial effect Effects 0.000 claims description 7
238000011260 co-administration Methods 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 6
208000016691 refractory malignant neoplasm Diseases 0.000 claims description 5
230000009261 transgenic effect Effects 0.000 claims description 5
108091007960 PI3Ks Proteins 0.000 claims description 3
230000002538 fungal effect Effects 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims 12
102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
210000004027 cell Anatomy 0.000 description 306
241000700159 Rattus Species 0.000 description 180
239000002953 phosphate buffered saline Substances 0.000 description 67
239000005557 antagonist Substances 0.000 description 65
108090000623 proteins and genes Proteins 0.000 description 62
201000011510 cancer Diseases 0.000 description 46
239000000243 solution Substances 0.000 description 45
239000012634 fragment Substances 0.000 description 42
108010047041 Complementarity Determining Regions Proteins 0.000 description 40
210000002950 fibroblast Anatomy 0.000 description 40
230000004913 activation Effects 0.000 description 39
101150022345 GAS6 gene Proteins 0.000 description 36
238000002474 experimental method Methods 0.000 description 36
239000003446 ligand Substances 0.000 description 36
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 35
230000027455 binding Effects 0.000 description 35
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 34
210000001519 tissue Anatomy 0.000 description 32
210000004881 tumor cell Anatomy 0.000 description 32
230000006907 apoptotic process Effects 0.000 description 31
230000005764 inhibitory process Effects 0.000 description 30
102000004169 proteins and genes Human genes 0.000 description 30
239000011534 wash buffer Substances 0.000 description 30
239000000872 buffer Substances 0.000 description 29
235000018102 proteins Nutrition 0.000 description 29
239000002609 medium Substances 0.000 description 28
239000000556 agonist Substances 0.000 description 24
238000000338 in vitro Methods 0.000 description 22
208000014197 Fetal anticonvulsant syndrome Diseases 0.000 description 21
238000001943 fluorescence-activated cell sorting Methods 0.000 description 21
238000003752 polymerase chain reaction Methods 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
238000002965 ELISA Methods 0.000 description 20
108010023337 axl receptor tyrosine kinase Proteins 0.000 description 20
241000699666 Mus <mouse, genus> Species 0.000 description 19
206010060862 Prostate cancer Diseases 0.000 description 18
230000012010 growth Effects 0.000 description 18
206010008342 Cervix carcinoma Diseases 0.000 description 17
208000000236 Prostatic Neoplasms Diseases 0.000 description 17
102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 17
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 17
201000010881 cervical cancer Diseases 0.000 description 17
229960004316 cisplatin Drugs 0.000 description 17
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 17
229960004679 doxorubicin Drugs 0.000 description 17
-1 human AXL Chemical compound 0.000 description 17
201000001441 melanoma Diseases 0.000 description 17
101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 description 16
206010061535 Ovarian neoplasm Diseases 0.000 description 16
239000001963 growth medium Substances 0.000 description 16
238000011534 incubation Methods 0.000 description 16
206010059866 Drug resistance Diseases 0.000 description 15
206010033128 Ovarian cancer Diseases 0.000 description 15
239000000203 mixture Substances 0.000 description 15
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 14
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
229940127089 cytotoxic agent Drugs 0.000 description 14
239000013604 expression vector Substances 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
108020004414 DNA Proteins 0.000 description 13
101000973901 Homo sapiens Tyrosine-protein kinase Mer Proteins 0.000 description 13
241000699670 Mus sp. Species 0.000 description 13
102000045684 human MERTK Human genes 0.000 description 13
230000005012 migration Effects 0.000 description 13
238000013508 migration Methods 0.000 description 13
238000010186 staining Methods 0.000 description 13
239000006228 supernatant Substances 0.000 description 13
108010001336 Horseradish Peroxidase Proteins 0.000 description 12
238000003556 assay Methods 0.000 description 12
238000010586 diagram Methods 0.000 description 12
238000000746 purification Methods 0.000 description 12
230000009467 reduction Effects 0.000 description 12
210000002966 serum Anatomy 0.000 description 12
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000002299 complementary DNA Substances 0.000 description 11
229960002949 fluorouracil Drugs 0.000 description 11
239000000523 sample Substances 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
229920001817 Agar Polymers 0.000 description 10
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 10
229920001213 Polysorbate 20 Polymers 0.000 description 10
238000002835 absorbance Methods 0.000 description 10
239000008272 agar Substances 0.000 description 10
230000035784 germination Effects 0.000 description 10
230000006698 induction Effects 0.000 description 10
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
230000004083 survival effect Effects 0.000 description 10
238000005406 washing Methods 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
108700020796 Oncogene Proteins 0.000 description 9
206010061902 Pancreatic neoplasm Diseases 0.000 description 9
239000004698 Polyethylene Substances 0.000 description 9
238000010367 cloning Methods 0.000 description 9
201000002528 pancreatic cancer Diseases 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
239000000758 substrate Substances 0.000 description 9
230000004565 tumor cell growth Effects 0.000 description 9
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
102000044589 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 8
108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 8
229930012538 Paclitaxel Natural products 0.000 description 8
208000005718 Stomach Neoplasms Diseases 0.000 description 8
230000000903 blocking effect Effects 0.000 description 8
230000003197 catalytic effect Effects 0.000 description 8
239000006285 cell suspension Substances 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
206010017758 gastric cancer Diseases 0.000 description 8
210000005260 human cell Anatomy 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
229960001592 paclitaxel Drugs 0.000 description 8
208000008443 pancreatic carcinoma Diseases 0.000 description 8
230000008569 process Effects 0.000 description 8
201000011549 stomach cancer Diseases 0.000 description 8
230000002195 synergetic effect Effects 0.000 description 8
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
230000005747 tumor angiogenesis Effects 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
108091026890 Coding region Proteins 0.000 description 7
108060003951 Immunoglobulin Proteins 0.000 description 7
239000002147 L01XE04 - Sunitinib Substances 0.000 description 7
241000282567 Macaca fascicularis Species 0.000 description 7
241000699660 Mus musculus Species 0.000 description 7
108010090804 Streptavidin Proteins 0.000 description 7
241000700605 Viruses Species 0.000 description 7
206010052428 Wound Diseases 0.000 description 7
208000027418 Wounds and injury Diseases 0.000 description 7
230000003321 amplification Effects 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
229960003668 docetaxel Drugs 0.000 description 7
238000003384 imaging method Methods 0.000 description 7
102000018358 immunoglobulin Human genes 0.000 description 7
238000010369 molecular cloning Methods 0.000 description 7
230000035772 mutation Effects 0.000 description 7
LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 7
238000003199 nucleic acid amplification method Methods 0.000 description 7
238000011580 nude mouse model Methods 0.000 description 7
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
239000000047 product Substances 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
229940034785 sutent Drugs 0.000 description 7
238000012360 testing method Methods 0.000 description 7
101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 6
241000283074 Equus asinus Species 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 6
101710204410 Scaffold protein Proteins 0.000 description 6
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 6
BTKMJKKKZATLBU-UHFFFAOYSA-N [2-(1,3-benzothiazol-2-yl)-1,3-benzothiazol-6-yl] dihydrogen phosphate Chemical compound C1=CC=C2SC(C3=NC4=CC=C(C=C4S3)OP(O)(=O)O)=NC2=C1 BTKMJKKKZATLBU-UHFFFAOYSA-N 0.000 description 6
229960000723 ampicillin Drugs 0.000 description 6
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
238000013459 approach Methods 0.000 description 6
230000009260 cross reactivity Effects 0.000 description 6
238000010828 elution Methods 0.000 description 6
210000004602 germ cell Anatomy 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
238000002372 labelling Methods 0.000 description 6
229960000485 methotrexate Drugs 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
239000012679 serum free medium Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
210000001685 thyroid gland Anatomy 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
238000013042 tunel staining Methods 0.000 description 6
206010005003 Bladder cancer Diseases 0.000 description 5
208000000461 Esophageal Neoplasms Diseases 0.000 description 5
208000008839 Kidney Neoplasms Diseases 0.000 description 5
206010030155 Oesophageal carcinoma Diseases 0.000 description 5
206010038389 Renal cancer Diseases 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
210000004102 animal cell Anatomy 0.000 description 5
229940034982 antineoplastic agent Drugs 0.000 description 5
238000005415 bioluminescence Methods 0.000 description 5
230000029918 bioluminescence Effects 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
229910002091 carbon monoxide Inorganic materials 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
208000029742 colonic neoplasm Diseases 0.000 description 5
239000012636 effector Substances 0.000 description 5
201000004101 esophageal cancer Diseases 0.000 description 5
201000003444 follicular lymphoma Diseases 0.000 description 5
239000012737 fresh medium Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
208000005017 glioblastoma Diseases 0.000 description 5
208000014829 head and neck neoplasm Diseases 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
201000010982 kidney cancer Diseases 0.000 description 5
208000014018 liver neoplasm Diseases 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
230000001613 neoplastic effect Effects 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
108091033319 polynucleotide Proteins 0.000 description 5
239000002157 polynucleotide Substances 0.000 description 5
102000040430 polynucleotide Human genes 0.000 description 5
230000005855 radiation Effects 0.000 description 5
108091008598 receptor tyrosine kinases Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
201000005112 urinary bladder cancer Diseases 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
102000047934 Caspase-3/7 Human genes 0.000 description 4
108700037887 Caspase-3/7 Proteins 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
208000007342 Diabetic Nephropathies Diseases 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
101000774835 Heteractis crispa PI-stichotoxin-Hcr2o Proteins 0.000 description 4
229920000209 Hexadimethrine bromide Polymers 0.000 description 4
101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 description 4
206010020880 Hypertrophy Diseases 0.000 description 4
102000043136 MAP kinase family Human genes 0.000 description 4
108091054455 MAP kinase family Proteins 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
208000000453 Skin Neoplasms Diseases 0.000 description 4
239000006180 TBST buffer Substances 0.000 description 4
208000024770 Thyroid neoplasm Diseases 0.000 description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
239000001506 calcium phosphate Substances 0.000 description 4
229910000389 calcium phosphate Inorganic materials 0.000 description 4
235000011010 calcium phosphates Nutrition 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
230000005754 cellular signaling Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000001816 cooling Methods 0.000 description 4
208000030381 cutaneous melanoma Diseases 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
208000033679 diabetic kidney disease Diseases 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
229960005420 etoposide Drugs 0.000 description 4
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
230000005284 excitation Effects 0.000 description 4
239000008098 formaldehyde solution Substances 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
229960005277 gemcitabine Drugs 0.000 description 4
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
230000001434 glomerular Effects 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
201000010536 head and neck cancer Diseases 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
210000004408 hybridoma Anatomy 0.000 description 4
206010020718 hyperplasia Diseases 0.000 description 4
238000003364 immunohistochemistry Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000006882 induction of apoptosis Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
239000010410 layer Substances 0.000 description 4
201000007270 liver cancer Diseases 0.000 description 4
239000006166 lysate Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
208000025113 myeloid leukemia Diseases 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
210000002307 prostate Anatomy 0.000 description 4
102000027426 receptor tyrosine kinases Human genes 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
201000000849 skin cancer Diseases 0.000 description 4
201000003708 skin melanoma Diseases 0.000 description 4
201000002510 thyroid cancer Diseases 0.000 description 4
238000003146 transient transfection Methods 0.000 description 4
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
208000023514 Barrett esophagus Diseases 0.000 description 3
208000023665 Barrett oesophagus Diseases 0.000 description 3
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
108091035707 Consensus sequence Proteins 0.000 description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
108010006785 Taq Polymerase Proteins 0.000 description 3
238000012452 Xenomouse strains Methods 0.000 description 3
239000013543 active substance Substances 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000003466 anti-cipated effect Effects 0.000 description 3
230000002001 anti-metastasis Effects 0.000 description 3
150000001540 azides Chemical class 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229960004117 capecitabine Drugs 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
230000002301 combined effect Effects 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
229960004397 cyclophosphamide Drugs 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
229960001904 epirubicin Drugs 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000010363 gene targeting Methods 0.000 description 3
108010004351 growth arrest-specific protein 6 Proteins 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
241000894007 species Species 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229940063683 taxotere Drugs 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229960000303 topotecan Drugs 0.000 description 3
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
238000001890 transfection Methods 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
210000000689 upper leg Anatomy 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000038030 PI3Ks Human genes 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
101150117115 V gene Proteins 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000005299 abrasion Methods 0.000 description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
229960000473 altretamine Drugs 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
238000011091 antibody purification Methods 0.000 description 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
230000005907 cancer growth Effects 0.000 description 2
229960004562 carboplatin Drugs 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
238000013375 chromatographic separation Methods 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000010372 cloning stem cell Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
229960000684 cytarabine Drugs 0.000 description 2
229960003901 dacarbazine Drugs 0.000 description 2
229960000640 dactinomycin Drugs 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
238000002224 dissection Methods 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
230000006862 enzymatic digestion Effects 0.000 description 2
229940082789 erbitux Drugs 0.000 description 2
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
229960001101 ifosfamide Drugs 0.000 description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
230000008676 import Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
229960004768 irinotecan Drugs 0.000 description 2
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000004705 lumbosacral region Anatomy 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
231100000590 oncogenic Toxicity 0.000 description 2
230000002246 oncogenic effect Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
208000023958 prostate neoplasm Diseases 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000011734 sodium Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
229960004964 temozolomide Drugs 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
229960000575 trastuzumab Drugs 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
229960002066 vinorelbine Drugs 0.000 description 2
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
239000008096 xylene Substances 0.000 description 2
WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
KSQPABRRLYOJAM-UHFFFAOYSA-N 1-cyclohexyl-3-methyl-1-nitrosourea Chemical compound CNC(=O)N(N=O)C1CCCCC1 KSQPABRRLYOJAM-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
XIFVTSIIYVGRHJ-UHFFFAOYSA-N 2-n,2-n,4-n,4-n,6-n-pentamethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N(C)C)=NC(N(C)C)=N1 XIFVTSIIYVGRHJ-UHFFFAOYSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
101710191936 70 kDa protein Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
102000015735 Beta-catenin Human genes 0.000 description 1
108060000903 Beta-catenin Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
238000007809 Boyden Chamber assay Methods 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
229940123587 Cell cycle inhibitor Drugs 0.000 description 1
231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
101150094690 GAL1 gene Proteins 0.000 description 1
102100028501 Galanin peptides Human genes 0.000 description 1
JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102100034062 Glutathione hydrolase 5 proenzyme Human genes 0.000 description 1
101710143566 Glutathione hydrolase 5 proenzyme Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000019298 Lipocalin Human genes 0.000 description 1
108050006654 Lipocalin Proteins 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
229930126263 Maytansine Natural products 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
102000014171 Milk Proteins Human genes 0.000 description 1
108010011756 Milk Proteins Proteins 0.000 description 1
229940121849 Mitotic inhibitor Drugs 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
241000255969 Pieris brassicae Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
108010059712 Pronase Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
238000010802 RNA extraction kit Methods 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100076570 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MER1 gene Proteins 0.000 description 1
101100033336 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) REC107 gene Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
229960001220 amsacrine Drugs 0.000 description 1
XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
239000012491 analyte Substances 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
229960001467 bortezomib Drugs 0.000 description 1
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000034196 cell chemotaxis Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
201000011024 colonic benign neoplasm Diseases 0.000 description 1
238000010293 colony formation assay Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
230000004154 complement system Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000009133 cooperative interaction Effects 0.000 description 1
238000009402 cross-breeding Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
230000021953 cytokinesis Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000010595 endothelial cell migration Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000003366 endpoint assay Methods 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229950002017 esorubicin Drugs 0.000 description 1
ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
101150092673 etk gene Proteins 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
229960004783 fotemustine Drugs 0.000 description 1
YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
229910003472 fullerene Inorganic materials 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229960002584 gefitinib Drugs 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000006481 glucose medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
230000003862 health status Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229960002899 hydroxyprogesterone Drugs 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
210000000738 kidney tubule Anatomy 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
229960004891 lapatinib Drugs 0.000 description 1
BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
238000011670 long-evans rat Methods 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000010232 migration assay Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000021239 milk protein Nutrition 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
108010093470 monomethyl auristatin E Proteins 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000004091 panning Methods 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008010 parenteral excipient Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960005079 pemetrexed Drugs 0.000 description 1
QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
238000002823 phage display Methods 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000002818 protein evolution Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
238000002702 ribosome display Methods 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
229940102127 rubidium chloride Drugs 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
238000005204 segregation Methods 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
101150111450 sky1 gene Proteins 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000009987 spinning Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229960001099 trimetrexate Drugs 0.000 description 1
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
230000006426 vascular sprouting Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
108090000195 villin Proteins 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

JP2010532510A 2007-11-12 2008-11-12 Ａｘｌ抗体 Expired - Fee Related JP5769969B2 (ja)